Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Chinthalapally V. Rao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5715-7979; OpenAlex author ID A5101461393; NIH RePORTER profile ID 14274989. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 12)
Trials
0
Grants
1
Labs led
1
Collaborators
42
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 1 paper · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers, 1 grant · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 23

  1. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Co-author DOI 10.1073/pnas.2315509121↗
  2. Pancreatic Cancer Disparities among Gender, Race, and Ethnicity: The PRECEDE Consortium Outcomes and Impact. First author DOI 10.1158/1940-6207.capr-23-0086↗
  3. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. Co-author DOI 10.1096/fj.201902826rr↗
  4. Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention. Last author DOI 10.1002/mc.23084↗
  5. Role of Dietary Cancer-Preventive Phytochemicals in Pancreatic Cancer Stem Cells. Last author DOI 10.1007/s40495-018-0145-2↗
  6. Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. Last author DOI 10.2174/0929867324666170209104453↗
  7. Immunoprevention of Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170223153509↗
  8. Pancreatic Cancer Chemoprevention: Challenges and Opportunities. First author DOI 10.2174/092986732522180704091601↗
  9. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras G12D/+ mice. Last author DOI 10.1111/imm.12746↗
  10. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Last author DOI 10.18632/oncotarget.22085↗
  11. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Co-author DOI 10.1097/mpa.0000000000000705↗
  12. Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-2820↗
  13. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Last author DOI 10.18632/oncotarget.3499↗
  14. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.5396↗
  15. Molecular Targeted Intervention for Pancreatic Cancer. Last author DOI 10.3390/cancers7030850↗
  16. New insights into pancreatic cancer stem cells. Co-author DOI 10.4252/wjsc.v7.i3.547↗
  17. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Last author DOI 10.1158/1940-6207.capr-14-0176↗
  18. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. Co-author DOI 10.1002/ijc.28285↗
  19. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0073940↗
  20. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Last author DOI 10.1593/tlo.13556↗
  21. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. Last author DOI 10.1593/neo.121508↗
  22. Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. Last author DOI 10.2174/092986712801661095↗
  23. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Last author DOI 10.1007/s10555-011-9311-2↗

Grants 1

  1. EFFECT OF A MULTIPEPTIDE KRAS VACCINE IN THE PREVENTION OF PANCREATIC CANCER DRIVEN BY KRAS ONCOPROTEIN HHSN2612015000371 TORFP: 2017-E02 26120150003↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Altaf Mohammed · 16 shared papers, 2011–2019 · strength 1.05
  2. Naveena B. Janakiram · 10 shared papers, 2011–2019 · strength 0.56
  3. Hiroshi Y. Yamada · 2 shared papers, 2015–2023 · strength 0.43
  4. Ming You · 1 shared grant, 2017 · strength 0.29
  5. Gaurav Kumar · 3 shared papers, 2015–2018 · strength 0.23
  6. Kamiya Mehla · 1 shared paper, 2024 · strength 0.18
  7. Divya Murthy · 1 shared paper, 2024 · strength 0.18
  8. Voddu Suresh · 1 shared paper, 2024 · strength 0.18
  9. Nina V. Chaika · 1 shared paper, 2024 · strength 0.18
  10. Ravi Kumar Thakur · 1 shared paper, 2024 · strength 0.18
  11. Pankaj Kumar Singh · 1 shared paper, 2024 · strength 0.18
  12. Michael Anthony Hollingsworth · 1 shared paper, 2024 · strength 0.18
  13. Surendra Kumar Shukla · 1 shared paper, 2024 · strength 0.18
  14. Kuldeep Singh Attri · 1 shared paper, 2024 · strength 0.18
  15. Resham Bhattacharya · 1 shared paper, 2020 · strength 0.09
  16. Xunhao Xiong · 1 shared paper, 2020 · strength 0.09
  17. Danny N. Dhanasekaran · 1 shared paper, 2020 · strength 0.09
  18. Priyabrata Mukherjee · 1 shared paper, 2020 · strength 0.09
  19. Courtney W. Houchen · 2 shared papers, 2013–2015 · strength 0.08
  20. Shubham Pant · 1 shared paper, 2015 · strength 0.07
  21. Peter J. Allen · 1 shared paper, 2016 · strength 0.05
  22. Mark Steven Miller · 1 shared paper, 2016 · strength 0.05
  23. Diane M. Simeone · 1 shared paper, 2016 · strength 0.05
  24. Alison P. Klein · 1 shared paper, 2016 · strength 0.05
  25. David M. Lubman · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.